Sanofi to launch Toujeo next week; Stada sees profits crash; White House takes on superbugs;

@FiercePharma: Jaguar Animal Health eyes a second run at IPO. Story from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: IPCA says FDA bans will have little sales impact. Didn't Wockhardt make that claim before its profits sank? FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Hey, European countries--join forces to bring down drug prices, WHO suggests. Article | Follow @CarlyHFierce

> Purdue Pharma may be on the hook for more than $1 billion after a judge ruled that it missed a filing deadline. More

> Sanofi ($SNY) says it will launch new diabetes med Toujeo in the U.S. next week. Report

> Germany drugmaker Stada Arzneimittel reported slightly higher sales but a 47% drop in net profit because of charges for issues in Eastern Europe and Asia. Release

> The White House will release a report laying out a 5-year plan for fighting antibiotic-resistant infections, including support for new antibiotics. Story

Medical Device News

@FierceMedDev: Olympus releases updated endoscope cleaning instructions amid pushback. Story | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: Dr. Reddy's shopping for deals up to $1B as it expands in injectable meds. Report | Follow @EmilyWFierce

> Google, J&J partner to advance surgical robotics. More

> Premier CEO says hospitals must integrate their supply chain to track spending on medical devices. Article

Biotech News

@FierceBiotech: EuroBiotech Report: Billionaires drive Malin to €330M IPO, Push for EU JOBS Act, RNAi stock jumps on PhIIa data. Read more | Follow @FierceBiotech

@JohnCFierce: ICYMI: Not giving up day job, but interviewing @Asthika from Bloomberg Intelligence on biotech market was fun. Watch | Follow @JohnCFierce

@DamianFierce: Early contender for next year's #FierceMadness: $LLY and Boehringer say Jardiance + metformin = Synjardy. | Follow @DamianFierce

> MorphoSys tanks after Celgene walks away from $818M pact. More

> Novo Nordisk speeds back to the FDA with its once-rejected insulin. Article

> Ohr Pharma's eye drop fails a Phase II AMD trial. Report

And Finally... Roseroot may help treat depression, a new study shows. More

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.